NCT03797404 (REMOMEPO) is a clinical trial in Asthma, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT03797404?

NCT03797404 is sponsored by Assistance Publique - Hôpitaux de Paris.

Is NCT03797404 still recruiting?

NCT03797404 is currently completed. Last updated 20 January 2023.

Last reviewed 2023-01-20 · How we verify

NCT03797404: REMOMEPO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Airway Remodeling During Mepolizumab Treatment

Completed Last updated 20 January 2023

What this trial tests

trial in Asthma in 37 participants. Completed in 21 June 2022.

Timeline

24 April 2019

Primary endpoint
21 June 2022

21 June 2022

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	Completed
Study type	OBSERVATIONAL
Enrollment	37
Start date	24 April 2019
Primary completion	21 June 2022
Estimated completion	21 June 2022
Sites	1 location across France

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic airway changes, such as smooth muscle hypertrophy/hyperplasia, reticular basement membrane (RBM) thickening, goblet cells hyperplasia characterize severe asthma. Chronic inflammation, and especially eosinophilia and T2 cytokines are involved in these structural changes. The aim of this prospective observational study is to assess airway changes, assessed by bronchial biopsies before treatment, then after 6 months and 12 months, induced by mepolizumab in 40 severe asthma patients who will receive the treatment as part of their standard care. Changes in RBM thickening, in airway smooth muscle (ASM) area, in the number of PGP9 sections will be assessed on bronchial biopsies after 6 months and 12 months of mepolizumab treatment. Bronchoalveolar lavage (BAL) levels of inflammatory and remodeling mediators and of extra-cellular matrix (ECM) components will be measured after 6 months and 12 months of mepolizumab treatment. Relationship between clinical response to mepolizumab and remodeling changes after 6 months and 12 months will be assessed.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Biologics and airway remodeling in severe asthma.
Varricchi G, Ferri S, Pepys J, Poto R, et al · · 2022 · cited 194× · PMID 35950646 · DOI 10.1111/all.15473
Holy Grail: the journey towards disease modification in asthma.
Busse WW, Melén E, Menzies-Gow AN. · · 2022 · cited 39× · PMID 35197266 · DOI 10.1183/16000617.0183-2021
Biologics and airway remodeling in asthma: early, late, and potential preventive effects.
Varricchi G, Poto R, Lommatzsch M, Brusselle G, et al · · 2025 · cited 33× · PMID 39520155 · DOI 10.1111/all.16382
Targeting inflammation or remodeling in asthma? Is there a right way?
Domvri K, Porpodis K. · · 2023 · cited 2× · PMID 38076243 · DOI 10.3389/fmed.2023.1241920
Impact of Mepolizumab on Airway Remodeling and Inflammation in Severe Eosinophilic Asthma.
Taillé C, Hamidi F, Heddebaut N, Poté N, et al · · 2026 · cited 1× · PMID 41354402 · DOI 10.1016/j.chest.2025.10.047
Decrease in Eosinophil-Derived-Neurotoxin With Mepolizumab Is Associated With Asthma Improvement.
Granger V, Nadif R, Orsi L, Chollet Martin S, et al · · 2025 · PMID 40785372 · DOI 10.1111/all.70008

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03797404 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 20 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03797404.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing